ABT-670 

ABT-670 is a selective, oral bioavailable agonist of dopamine D₄ receptor, with EC₅₀ of 89 nM, 160 nM, and 93 nM for human D₄, ferret D₄, and rat D₄, respectively.

ABT-670 is a selective D₄ agonist, with EC₅₀ of 89 nM, 160 nM, and 93 nM for human D₄, ferret D₄, and rat D₄, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ABT-670 (0.1 μmol/kg) robustly induces a high (75%) incidence of erections in male rats. ABT-670 exhibits excellent oral bioavailability in rat, dog, and monkey (68%, 85%, and 91%, respectively) with comparable efficacy, safety, and tolerability^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

325.40

C₁₉H₂₃N₃O₂

630119-43-6

O=C(NCN1CCC(C2=CC=CC=[N+]2[O-])CC1)C3=CC=CC(C)=C3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Patel MV, et al. Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. J Med Chem. 2006 Dec 14;49(25):7450-65.  [Content Brief]